Global Patent Index - EP 4342530 A1

EP 4342530 A1 20240327 - SORTILIN MODULATORS

Title (en)

SORTILIN MODULATORS

Title (de)

SORTILIN MODULATOREN

Title (fr)

MODULATEURS DE LA SORTILINE

Publication

EP 4342530 A1 20240327 (EN)

Application

EP 22193792 A 20220902

Priority

EP 22193792 A 20220902

Abstract (en)

The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositions comprising the compounds of the invention, and to their use in the treatment or prevention of medical conditions in which modulation of sortilin is beneficial.

IPC 8 full level

A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 27/16 (2006.01); A61P 35/00 (2006.01); C07C 229/14 (2006.01); C07D 213/36 (2006.01); C07D 215/06 (2006.01); C07D 215/227 (2006.01); C07D 249/08 (2006.01); C07D 263/58 (2006.01); C07D 265/36 (2006.01); C07D 307/78 (2006.01); C07D 307/87 (2006.01); C07D 311/76 (2006.01); C07D 317/58 (2006.01); C07D 319/18 (2006.01)

CPC (source: EP)

A61P 9/00 (2018.01); A61P 9/04 (2018.01); A61P 9/10 (2018.01); A61P 25/00 (2018.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 27/16 (2018.01); A61P 35/00 (2018.01); C07C 229/14 (2013.01); C07C 309/04 (2013.01); C07D 213/36 (2013.01); C07D 215/06 (2013.01); C07D 215/227 (2013.01); C07D 249/08 (2013.01); C07D 263/58 (2013.01); C07D 265/36 (2013.01); C07D 307/78 (2013.01); C07D 307/87 (2013.01); C07D 311/76 (2013.01); C07D 317/58 (2013.01); C07D 319/18 (2013.01); C07D 491/052 (2013.01); C07D 491/056 (2013.01); C07B 2200/07 (2013.01); C07C 2602/08 (2017.05); C07C 2602/10 (2017.05)

Citation (applicant)

  • US 2016331746 A1 20161117 - PATEL NIKETA A [US], et al
  • WO 2021116290 A1 20210617 - UNIV AARHUS [DK], et al
  • CELL, vol. 118, no. 2, 2004, pages 243 - 255
  • BAKER, M. ET AL.: "Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome", NATURE, vol. 442, no. 7105, 2006, pages 916 - 919, XP008101482, DOI: 10.1038/NATURE05016
  • ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 70, 2014, pages 451 - 460
  • NEUROLOGY, vol. 71, no. 9, 2008, pages 656 - 664
  • PSYCHIATRY, vol. 5, no. e677, 2015, pages 1 - 7
  • J ALZHEIMERS DIS, vol. 27, no. 4, 2011, pages 781 - 790
  • CARRASQUILLO, M. ET AL.: "Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma", AM J HUM GENET, vol. 87, no. 6, 2010, pages 890 - 897
  • CHEN, Z. Y: "Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway", J NEUROSCI, vol. 25, no. 26, 2005, XP055346388, DOI: 10.1523/JNEUROSCI.1017-05.2005
  • TRENDS GENET, vol. 24, no. 4, 2008, pages 186 - 194
  • DE MUYNCK, L. ET AL.: "The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding", NEUROBIOL AGING, vol. 34, no. 11, 2013, pages 2541 - 2547, XP028691739, DOI: 10.1016/j.neurobiolaging.2013.04.022
  • J NEUROINFLAMMATION, vol. 10, 2013, pages 105
  • GALIMBERTI, D. ET AL.: "GRN variability contributes to sporadic frontotemporal lobar degeneration", J ALZHEIMERS DIS, vol. 19, no. 1, 2010, pages 171 - 177
  • GALIMBERTI, D. ET AL.: "Progranulin as a therapeutic target for dementia", EXPERT OPIN THER TARGETS, vol. 22, no. 7, 2018, pages 579 - 585, XP055820718, DOI: 10.1080/14728222.2018.1487951
  • DNA AND CELL BIOLOGY, vol. 36, no. 12, 2017, pages 1050 - 1061
  • MOL NEURODEGENER, vol. 7, 2012, pages 33
  • GASS, J. ET AL.: "Progranulin: an emerging target for FTLD therapies", BRAIN RES, vol. 1462, 2012, pages 118 - 128, XP028521745, DOI: 10.1016/j.brainres.2012.01.047
  • GIJSELINCK, I.: "Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update", HUM MUTAT, vol. 29, no. 12, 2008
  • GOETTSCH, C. ET AL.: "Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases. Atherosclerosis", THROMBOSIS AND VASCULAR BIOLOGY, vol. 38, no. 1, 2017, pages 19 - 25
  • JANSEN, P. ET AL.: "Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury", NATURE NEUROSCIENCE, vol. 10, no. 11, 2007, XP002478373, DOI: 10.1038/nn2000
  • NEURON, vol. 68, no. 4, 2010, pages 654 - 667
  • HUANG, G. ET AL.: "Insulin responsiveness of glucose transporter 4 in 3T3-L1 cells depends on the presence of sortilin", MOL BIOL CELL, vol. 24, no. 19, 2013, pages 3115 - 3122
  • KADDAI, V. ET AL.: "Involvement of TNF-a in abnormal adipocyte and muscle sortilin expression in obese mice and humans", DIABETOLOGIA, vol. 52, 2009, pages 932 - 940, XP019698548
  • KJOLBY, M. ET AL.: "Sort1, encoded by the cardiovascular risk locus 1 p13.3, is a regulator of hepatic lipoprotein export", CELL METAB, vol. 12, no. 3, 2010, pages 213 - 223
  • LAIRD, A. S. ET AL.: "Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy", PLOS ONE, vol. 5, no. 10, 2010, pages e13368
  • LEE, W. ET AL.: "Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency", HUM MOL GENET, vol. 23, no. 6, 2014, pages 1467 - 1478, XP055193340, DOI: 10.1093/hmg/ddt534
  • MARTENS, L. ET AL.: "Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury", J CLIN INVEST, vol. 122, no. 11, 2012, pages 3955 - 3959
  • MAZELLA, J. ET AL.: "The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor", J BIOL CHEM, vol. 273, no. 41, 1998, pages 26273 - 26276, XP002294172, DOI: 10.1074/jbc.273.41.26273
  • FRONT NEUROSCI, vol. 14, 2020, pages 586107
  • FRONTIERS IN CARDIOVASCULAR MEDICINE, vol. 8, 2021, pages 652584
  • MORTENSEN, M.B. ET AL.: "Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis", J CLIN INVEST, vol. 124, no. 12, 2014, pages 5317 - 5322
  • NATURE, vol. 427, no. 6977, 2014, pages 843 - 848
  • NYKJAER, A.WILLNOW, T. E: "Sortilin: a receptor to regulate neuronal viability and function", TRENDS NEUROSCI, vol. 35, no. 4, 2012, pages 261 - 270
  • OH, T.J. ET AL.: "Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus", CARDIOVASCULAR DIABETOLOGY, 2017
  • PAN, X. ET AL.: "Sortilin and retromer mediate retrograde transport of Glut4 in 3T3-L1 adipocytes", MOL BIOL CELL, vol. 28, no. 12, 2017, pages 1667 - 1675
  • J BIOL CHEM, vol. 272, no. 6, 1997, pages 3599 - 3605
  • AM J PATHOL, vol. 778, no. 1, 2011, pages 284 - 295
  • POTTIER, C. ET AL.: "Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study", LANCET NEUROL, vol. 17, no. 6, 2018, pages 548 - 558
  • QUISTGAARD, E. ET AL.: "Ligands bind to Sortilin in the tunnel of a ten-bladed beta-propeller domain", NAT STRUCT MOL BIOL, vol. 16, no. 1, 2009, pages 96 - 98, XP007909605, DOI: 10.1038/nsmb.1543
  • SANTOS, A. M. ET AL.: "Sortilin Participates in Light-dependent Photoreceptor Degeneration in Vivo", PLOS ONE, vol. 7, no. 4, 2012, pages e36243 - e36243
  • SHI, J.KANDROR, K. V.: "Sortilin Is Essential and Sufficient for the Formation of Glut4 Storage Vesicles in 3T3-L1 Adipocytes", DEVELOPMENTAL CELL, 2005
  • SCHRODER, T. ET AL.: "The identification of AF38469: an orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin", BIOORG MED CHEM LETT, vol. 24, no. 1, 2014, pages 177 - 180, XP055379658, DOI: 10.1016/j.bmcl.2013.11.046
  • SHENG, J. ET AL.: "Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer's disease", GENE, vol. 542, no. 2, 2014, pages 141 - 145
  • J BIOL CHEM, vol. 21, no. 287, 2012, pages 43798 - 43809
  • EUR J NEUROSCIENCE, vol. 33, no. 4, 2020, pages 622 - 31
  • TANG, W. ET AL.: "The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice", SCIENCE, vol. 332, no. 6028, 2011, pages 478 - 484, XP055119876, DOI: 10.1126/science.1199214
  • TAO, J. ET AL.: "Neuroprotective effects of progranulin in ischemic mice.", BRAIN RES, vol. 1436, 2012, pages 130 - 136, XP028445133, DOI: 10.1016/j.brainres.2011.11.063
  • TENK, H.K. ET AL.: "ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin", J NEUROSCIENCE, vol. 10, no. 11, 2005
  • VAN KAMPEN, J. M.: "Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson's disease", PLOS ONE, vol. 9, no. 5, 2014, pages e97032, XP055415418, DOI: 10.1371/journal.pone.0097032
  • NAT REV NEUROSCI, vol. 9, no. 12, 2008, pages 899 - 909
  • WILLNOW, T.E. ET AL.: "Sortilins: new players in lipoprotein metabolism", CURRENT OPINION IN LIPIDOLOGY, vol. 22, no. 2, 2011, pages 79 - 85
  • WUTS, P.G.M. AND GREENE, T.W: "Synthesis", 2006, JOHN WILEY AND SONS
  • FROTIERS IN NEUROANATOMY, vol. 13, no. 31, 2019, pages 1 - 27
  • YANO, H. ET AL.: "Proneurotrophin-3 is a neuronal apoptotic ligand: evidence for retrograde-directed cell killing", J NEUROSCI, vol. 29, no. 47, 2009, pages 14790 - 14802
  • YIN, F. ET AL.: "Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice", J EXP MED, vol. 207, no. 1, 2010
  • ZHENG, Y. ET AL.: "C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking", PLOS ONE, vol. 6, no. 6, 2011
  • J CELL BIOL, vol. 210, no. 6, 2015, pages 991 - 1002
  • NEURODEGENERATION, vol. 16, 2021, pages 84
  • PRUDENCIO ET AL.: "Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor", PROC NATL ACAD SCI USA, 2012
  • BEEL ET AL.: "Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice", MOL NEURODEGENER, vol. 13, 2018, pages 55, XP055747914, DOI: 10.1186/s13024-018-0288-y

Citation (search report)

  • [AD] TENNA JUUL SCHRØDER ET AL: "The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 1, 27 November 2013 (2013-11-27), Amsterdam NL, pages 177 - 180, XP055379658, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2013.11.046
  • [X] DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 23 March 2018 (2018-03-23), AURORA FINE CHEMICALS: "N-[(2,3-Dihydro-1H-inden-4-yl)methyl]-5,5-dimethylnorleucine", XP002808395, Database accession no. 2197279-42-6
  • [X] DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 23 March 2018 (2018-03-23), AURORA FINE CHEMICALS, XP002808397, Database accession no. 2197262-75-0
  • [X] DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 23 March 2018 (2018-03-23), AURORA FINE CHEMICALS: "5,5-Dimethyl-N-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]norleucine", XP002808398, Database accession no. 2197214-66-5
  • [X] DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; AURORA FINE CHEMICALS: "N-[(2,3-Dihydro-1,4-benzodioxin-5-yl)methyl]-5,5-dimethylnorleucine", XP002808399, Database accession no. 2197213-62-8

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

EP 4342530 A1 20240327; TW 202423910 A 20240616; WO 2024047227 A1 20240307

DOCDB simple family (application)

EP 22193792 A 20220902; EP 2023074028 W 20230901; TW 112133342 A 20230901